Targeted therapies for the myeloid leukaemias Journal Article

  


Authors: Maslak, P.; Scheinberg, D.
Article Title: Targeted therapies for the myeloid leukaemias
Abstract: Although the standard approach to myeloid leukaemias remains chemotherapy, the agents currently available rarely result in cure. Recent advances in understanding the biology of these disorders have lead to the development of targeted treatment strategies. In acute promyelocytic leukaemia (APL), all-trans retinoic acid (ATRA), sodium phenylbutyrate and arsenic trioxide are agents which either induce differentiation or apoptosis and have been used to successfully achieve remission. The tyrosine kinase inhibitor, STI-571, antisense oligonucleotides, and bcr-abl vaccines are strategies which focus on the oncogenic events in chronic myelogenous leukaemia (CML). Two anti-CD33 monoclonal antibody conjugates, Y90-HuM195 and CMA-676, have been used in acute myelogenous leukaemia (AML) and have shown some efficacy. Although the preliminary results with these targeted therapies are promising, further studies are needed to establish them as effective, less toxic alternatives to the current standard of care.
Keywords: unclassified drug; major clinical study; clinical trial; review; antineoplastic agents; drug targeting; animals; imatinib; apoptosis; cell differentiation; monoclonal antibodies; monoclonal antibody; protein tyrosine kinase inhibitor; arsenic trioxide; antibodies, monoclonal; cancer vaccine; leukemia, myeloid; acute myeloblastic leukemia; retinoic acid; meta analysis; vaccines; gemtuzumab ozogamicin; leukaemia; myeloid leukemia; antisense oligodeoxynucleotide; antisense oligonucleotides; humans; human; sodium phenylbutyrate; y90 hum195
Journal Title: Expert Opinion on Investigational Drugs
Volume: 9
Issue: 6
ISSN: 1354-3784
Publisher: Taylor & Francis Group  
Date Published: 2000-01-01
Start Page: 1197
End Page: 1205
Language: English
PUBMED: 11060736
PROVIDER: scopus
DOI: 10.1517/13543784.9.6.1197
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-0034079391&partnerID=40&md5=1960a8896fac093cce531e8199b3bdaa
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. David Scheinberg
    499 Scheinberg
  2. Peter Maslak
    197 Maslak
Related MSK Work